Current Report Filing (8-k)
December 05 2016 - 8:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 5, 2016
Minerva Neurosciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36517
|
|
26-0784194
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
1601 Trapelo Road
Suite 284
Waltham,
MA
|
|
02451
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(Registrants telephone number, including area code): (617) 600-7373
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01
Regulation FD Disclosure
On December 5, 2016, Minerva Neurosciences, Inc. (the Company) issued a press release announcing its presentations of data from the Companys
Phase IIA and Phase IIB trials with MIN-101 and Phase IIA trial with MIN-117 at the 55
th
Annual Meeting of the American College of Neuropsychopharmacology.
A copy of the above referenced press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. This information, including the information
contained in the press release furnished as Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of the Companys
filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.
Item 9.01.
Financial
Statements and Exhibits
(d) Exhibits
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press Release of the Company dated December 5, 2016
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
MINERVA NEUROSCIENCES, INC.
|
|
|
By:
|
|
/s/ Mark S. Levine
|
Name:
|
|
Mark S. Levine
|
Title:
|
|
Senior Vice President, General Counsel and Secretary
|
Date: December 5, 2016
INDEX OF EXHIBITS
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press Release of the Company dated December 5, 2016
|
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024